An expert panel of clinicians has developed a world-first set of quality indicators for primary hyperparathyroidism care in a bid to optimise management and cost-effectiveness.

Using a consensus-based approach, the Canadian researchers have proposed 18 individual indicators for the diagnosis and treatment  of primary hyperparathyroidism (pHPT).

They also listed the top five quality indicators (QIs) specific to primary care practitioners, endocrinologists and surgeons to pinpoint areas of improvement.

“Ultimately, if clinicians … can use this paper as part of their common-sense approach in guiding a more standardised and evidence-based management of parathyroid disease, patients who are affected will be better served,” said co-author and endocrine surgeon Dr Jesse Pasternak, from the University of Toronto.